rs3804099 — TLR2

TLR2 rs3804099 — A Silent Change With a Functional Shadow

Not all genetic variants that matter change an amino acid. Toll-Like Receptor 2 (TLR2)¹¹ Toll-Like Receptor 2 (TLR2)
the frontline innate immune receptor that detects bacterial lipoproteins, peptidoglycan, and mycobacterial components on the surface of macrophages and dendritic cells carries a synonymous variant — rs3804099, also written as T597C or 19216T/C — where a single nucleotide change in the coding sequence leaves the encoded amino acid identical but may not leave TLR2 function unchanged. In silico analysis predicts a 70% probability that the C allele creates or disrupts a splice site, potentially altering TLR2 mRNA processing and steady-state transcript levels. The variant has been studied across tuberculosis cohorts, cancer registries, inflammatory bowel disease treatment trials, and bacterial infection datasets, painting a picture of a functionally relevant variant whose effect is population-specific and context-dependent.

The rs3804099 C allele is the minor allele in most populations, with frequencies ranging from roughly 12% in Africans to 40% in East Asians, making it far more common globally than the R753Q variant (rs5743708) in the same gene, which is almost exclusively European. This means most users encountering TLR2 findings will have rs3804099 results rather than R753Q results.

The Mechanism

Unlike the R753Q missense variant (rs5743708)²² R753Q missense variant (rs5743708)
which directly disrupts TLR2's TIR domain structure, reducing signaling by 42-fold, rs3804099 does not change the TLR2 protein sequence. Instead, it operates at the RNA level. The nucleotide substitution (c.597T>C in some annotations, placed in exon 3 of TLR2) is predicted to alter splicing regulatory elements³³ splicing regulatory elements
exonic splicing enhancers and silencers that guide spliceosome assembly. An in silico analysis found a 70% probability that this substitution affects mRNA splicing, a mechanism increasingly recognized as a route through which synonymous variants influence gene function. A 2022 study in smokers and COPD patients found that individuals with CC homozygosity had significantly less FEV1 decline and that CT heterozygotes showed reduced neutrophil and macrophage numbers over time compared with TT individuals, consistent with altered TLR2 expression or isoform usage. A 2024 study examining TLR-2 expression in response to SARS-CoV-2 spike protein found that C allele carriers (CT and CC genotypes) could not mount the same downregulation of TLR-2 positive non-switched B cells as TT individuals, indicating that the C allele changes how TLR2 responds to viral challenge at the cellular level.

The Evidence

The clearest signal comes from cancer susceptibility, where rs3804099 consistently shows a modest protective effect of the C allele. A meta-analysis of 47 case-control studies comprising 15,851 cancer cases and 21,182 controls⁴⁴ 47 case-control studies comprising 15,851 cancer cases and 21,182 controls
spanning gastric, hepatocellular, colorectal, and other cancers found that carriers of the C allele (CT or CC genotypes) had significantly lower cancer risk compared with TT homozygotes, with overall OR of 0.85 (95% CI 0.74–0.97, p=0.016) in the dominant model. The effect was strongest in Asians (OR 0.69 for CT vs TT, 95% CI 0.55–0.87), consistent with the higher baseline C allele frequency in East Asian populations. For hepatocellular carcinoma specifically, the heterozygous CT genotype was associated with significantly decreased HCC risk compared to TT, in a study of 300 HCC cases and 360 controls. The biological interpretation is that the C allele may increase TLR2-mediated innate immune surveillance of malignant or pre-malignant cells, though the exact mechanism remains under investigation.

For tuberculosis, the picture is more complex. An individual case-control study in 341 Han Chinese TB patients and 386 controls⁵⁵ 341 Han Chinese TB patients and 386 controls
including 230 pulmonary TB and 111 tuberculous meningitis patients found that the CC genotype was associated with increased pulmonary TB susceptibility in a recessive model (OR 2.22, 95% CI 1.18–4.17), with the association specific to pulmonary rather than meningeal TB and more pronounced in males. A Western Chinese cohort found significant associations specifically in retreatment TB (patients who relapsed or failed initial therapy) rather than primary TB. A Han Taiwanese study identified a C-T haplotype across rs3804099 and the adjacent rs3804100 that conferred increased TB risk. However, meta-analyses tell a more cautious story: an earlier Asian-focused meta-analysis of 8 studies (2,175 TB cases, 2,069 controls) found no significant association across genetic models for the T597C variant (OR 0.95, 95% CI 0.86–1.04). A broader meta-analysis found modest significance in the overall pooled population. This discrepancy reflects heterogeneity across populations, TB types, and analytic models — the CC genotype may represent a genuine risk factor in specific ethnic or epidemiological contexts rather than a universal effect.

In inflammatory bowel disease, rs3804099 emerged from a systematic review as a predictor of anti-TNF drug response. A Danish study of 738 IBD patients treated with infliximab or adalimumab⁶⁶ Danish study of 738 IBD patients treated with infliximab or adalimumab
including 256 UC patients and 482 CD patients found that patients carrying the CT or CC genotype had more than twice the odds of responding to anti-TNF therapy compared with TT homozygotes (OR 2.17, 95% CI 1.35–3.47). The authors proposed that genetically determined reduced IL-1β and IL-6 production (associated with the C allele) may create a lower baseline inflammatory tone that responds more favorably to TNF blockade. This is a pharmacogenomic finding, not a disease susceptibility finding — having the C allele does not predispose to IBD, but if you develop IBD and require biologic therapy, it may predict your response.

Practical Implications

The clinical picture from rs3804099 is genuinely nuanced. The CC genotype occupies an unusual position: it appears to be a risk factor for pulmonary tuberculosis (in certain Asian populations and specifically in retreatment TB contexts), yet simultaneously confers modest protection against several cancers and better response to anti-TNF therapy in IBD. This paradox may reflect the immunological trade-off at the heart of TLR2 biology — a TLR2 that responds more vigorously (TT) is better at initial mycobacterial clearance but may also drive more cancer-promoting chronic inflammation; a TLR2 with altered expression or splicing (CC) may mount a blunted initial anti-mycobacterial response while reducing chronic inflammatory cancer risk.

For the TT genotype, which is the common form, the evidence suggests somewhat more robust initial TLR2-mediated innate immune responses, but without the cancer-protective attenuation of chronic signaling.

Interactions

rs3804099 is studied together with rs3804100⁷⁷ rs3804100
a closely adjacent synonymous TLR2 variant in exon 3 in strong linkage disequilibrium with rs3804099 in Asian populations in haplotype analyses — the C-T haplotype (rs3804099 C + rs3804100 T) appears to be the TB-risk haplotype in Han Taiwanese, suggesting the two variants act together or that rs3804099 tags a broader functional haplotype block.

For individuals who also carry TLR2 R753Q (rs5743708), the innate immune system faces both a structural signaling defect (R753Q) and a potential expression-level alteration (rs3804099) at the same gene, though these two variants are on different haplotype blocks and both appear to reach significance independently in TB studies. Their combined effect has not been formally studied.